Publications by authors named "Thu Thủy Vu"
Article Synopsis
- * There has been promising research into advanced cell therapies for SLE, including hematopoietic stem cell transplantation, mesenchymal stem cells, regulatory T cells, natural killer cells, and CAR T cells, though each has its pros and cons based on clinical trials.
- * Ongoing studies are needed to determine the safety and effectiveness of these cell-based therapies, and the review also addresses how to choose the best therapy for individual patients with SLE.
Mesenchymal stem cells (MSCs) have emerged as promising cell-based therapies in the treatment of degenerative and inflammatory conditions. However, despite accumulating evidence of the breadth of MSC functional potency, their broad clinical translation is hampered by inconsistencies in therapeutic efficacy, which is at least partly due to the phenotypic and functional heterogeneity of MSC populations as they progress towards senescence in vitro. MSC senescence, a natural response to aging and stress, gives rise to altered cellular responses and functional decline.
View Article and Find Full Text PDFResearch has advanced considerably since the first clinical trial of human mesenchymal stem cells (MSCs) in the early 1990s. During this period, our understanding of MSC biology and our ability to expand and manipulate these cells have provided hope for the repair of damaged tissues due to illness or injury. MSCs have conventionally been injected systemically or locally into target tissue; however, inconsistent cell homing and engraftment efficiencies represent a major bottleneck that has led to mixed results in clinical studies.
View Article and Find Full Text PDFPrimary cardiac angiosarcoma is an extremely rare, high-grade malignancy. Here, we describe the case of a 44-year-old male patient with a heart tumor in the left atrium wall, which caused a large amount of pericardial effusion that invaded the surrounding area and is visible on transthoracic echocardiography, computed tomography, and magnetic resonance imaging. The postoperative histopathological results confirmed this case as a primary cardiac epithelioid angiosarcoma.
View Article and Find Full Text PDFArticle Synopsis
- A cardiac cavernous hemangioma is a rare, benign tumor typically found in younger patients, but a case involving a 71-year-old male was reported.
- During a routine transthoracic echocardiogram, doctors found the heart tumor, which was not detected by triple-phase CT scans.
- The tumor was successfully removed via surgery, and post-operative examination confirmed it was a benign cavernous hemangioma, with the patient recovering within two weeks.